Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Buspirone
The First People's Hospital of Lianyungang
Anxiety Disorders
1 trial -
CAR-CD19 T cell
The First People's Hospital of Lianyungang
B Cell Lymphoma
1 trial -
CCTA, CT-MPI, DSA, FFR
The First People's Hospital of Lianyungang
Coronary Microvascular Disease
1 trial -
CD19 CAR-T cells infusion
The First People's Hospital of Lianyungang
Non Hodgkin Lymphoma
1 trial -
CMOP+Chidamide
The First People's Hospital of Lianyungang
Newly Diagnosed Peripheral T-cell Lymphoma
1 trial -
CT-FFR assessment
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
CT0590 CAR T Cells
The First People's Hospital of Lianyungang
Relapsed and/or Refractory Multiple Myeloma
1 trial -
CT0594CP
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
Cadonilimab
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial -
Canagliflozin
The First People's Hospital of Lianyungang
Type 2 Diabetes Mellitus With Complication
1 trial -
Carrelizumab
The First People's Hospital of Lianyungang
Cholangiocarcinoma
1 trial -
Carrelizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Cefotiam
The First People's Hospital of Lianyungang
Gastric Varices
1 trial -
Celecoxib
The First People's Hospital of Lianyungang
Low Back Pain
1 trial -
Chemotherapy drug
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma, Adult
1 trial -
Chi-GVM
The First People's Hospital of Lianyungang
Relapsed/Refractory Peripheral T-cell Lymphoma
1 trial -
Chinese herbal medicine
The First People's Hospital of Lianyungang
Acute on Chronic Liver Failure
1 trial -
Combination Product: Conventional third-line therapy
The First People's Hospital of Lianyungang
Colorectal Cancer (CRC)
1 trial -
Combination of chemotherapy and immunotherapy
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Combination of targeted biopsy and systematic biopsy
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
Contrast-enhanced ultrasound-guided core biopsy
The First People's Hospital of Lianyungang
Pancreatic Disease
1 trial -
Control lidocaine cream
The First People's Hospital of Lianyungang
Atopic Dermatitis
1 trial -
Controlled low central venous pressure (CLCVP) technology
The First People's Hospital of Lianyungang
Acute Kidney Injury
1 trial -
Conventional second-line therapy
The First People's Hospital of Lianyungang
Colorectal Cancer (CRC)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources